Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction - Test2 - elhamkhani - TriplyDB

Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction

Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction

http://www.wikidata.org/entity/Q27677509

about

Targeting Protein-Protein Interactions in the HIF System Cyclic and Macrocyclic Peptides as Chemical Tools To Recognise Protein Surfaces and Probe Protein-Protein Interactions Focusing on shared subpockets - new developments in fragment-based drug discovery Targeting the androgen receptor with steroid conjugates Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities Small-Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1α Dissecting Fragment-Based Lead Discovery at the von Hippel-Lindau Protein:Hypoxia Inducible Factor 1α Protein-Protein Interface Multimeric Complexes among Ankyrin-Repeat and SOCS-box Protein 9 (ASB9), ElonginBC, and Cullin 5: Insights into the Structure and Assembly of ECS-type Cullin-RING E3 Ubiquitin Ligases Is NMR Fragment Screening Fine-Tuned to Assess Druggability of Protein–Protein Interactions?Discovery of novel inhibitors disrupting HIF-1α/von Hippel-Lindau interaction through shape-based screening and cascade docking Potent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibition NMR approaches in structure-based lead discovery: recent developments and new frontiers for targeting multi-protein complexes Targeting Cullin-RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation.Small-molecule inhibitors of protein-protein interactions: progressing toward the reality.HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins.Catalytic in vivo protein knockdown by small-molecule PROTACs.Induced protein degradation: an emerging drug discovery paradigm.Biophysical screening for the discovery of small-molecule ligands.Insights into Cullin-RING E3 ubiquitin ligase recruitment: structure of the VHL-EloBC-Cul2 complex Ligand deconstruction: Why some fragment binding positions are conserved and others are not State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors.E3 Ubiquitin Ligase VHL Regulates Hypoxia-Inducible Factor-1α to Maintain Regulatory T Cell Stability and Suppressive Capacity.Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway Focused grid-based resampling for protein docking and mapping.Hypoxia as a therapy for mitochondrial disease.Characterization of biaryl torsional energetics and its treatment in OPLS all-atom force fields PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies.Emerging therapies targeting the ubiquitin proteasome system in cancer Binding of small molecules at interface of protein-protein complex - A newer approach to rational drug design.Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system NMR-based approaches for the identification and optimization of inhibitors of protein-protein interactions.Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds.Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Chemical Methods to Knock Down the Amyloid Proteins.Drugging the undruggable: targeting challenging E3 ligases for personalized medicine.Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.Targeted Protein Degradation by Small Molecules.Targeted protein knockdown using small molecule degraders.

P2860

Q26753176-2F8E7D89-1E9B-4ACA-8790-B11484ECEE6C Q26777298-C65E0F94-FA63-4701-BC01-C4631DC8F375 Q26795719-E84FAFA7-6F49-4777-9959-0FA409661679 Q26995692-58783F1B-07F4-41B8-8570-B6095F1F6DEF Q27640584-0DAAD721-FCBF-4626-8211-B6591214F571 Q27674529-4D1485EC-5DE8-45C1-832B-774030C05C2F Q27674729-0B09512A-55F1-4AD4-B027-CF05DA9EDD4B Q27679000-3F0EDCD0-3BFB-4CD4-BDC7-D7FBAD5282B5 Q27681373-D198913D-4B4B-4D8A-9C5F-3C2DD002410A Q28817163-42EDD706-A4A8-4A1A-B9A0-728EF5BB5F7C Q28822022-59C34D99-2348-460E-9A83-956D59638C29 Q30366295-9FFD22C5-DF38-4857-B104-BE023B773558 Q34043797-ABBDFD6C-D005-43BD-920B-D3D78D3F986A Q34263719-6C5A5BB7-DC0C-437A-AEA3-513C1BB38822 Q34480529-D194A00C-59F0-4766-BEA4-BA3197AAEE8B Q34480735-23BF7DA3-C79D-4A1C-B3CD-819F9794F113 Q34545841-77582158-F52F-4BC7-A18A-BC9F28266B62 Q34752496-3FAB25D3-A7EC-47FE-9820-D93CD76FDA61 Q35152151-A9A51378-5538-45E3-A999-610AA5B94A88 Q35616254-3B700463-23E4-43ED-8CF2-D8CB0B356E71 Q35738960-42273661-0D87-4174-A893-122EBAA9F93D Q35837701-45DF9B34-E5D6-47DF-982E-9B2F0971C6C1 Q36309724-909FA56B-E0B7-4AC2-AD14-381E7CC09B18 Q36746240-0491011A-9E13-44CF-BDEC-5F5ADB653001 Q36882394-146D453D-ACAF-4824-93A4-D2BFC6C0685E Q36999047-E2113CD8-533A-4201-A6D6-05B5364244E2 Q37065079-8C19C789-88F8-48EB-A334-74959465C490 Q37252274-D7017024-8C25-4001-9587-403078F9535B Q37410632-F27A4E5D-FB10-479B-BFEE-AD5EB3432960 Q37610874-F3C35540-1F9A-4B67-B515-613F7DB4AA23 Q38181445-27EC033D-5C63-4C84-9C0A-64D51B52DA12 Q38203020-35BB8487-0A08-409F-917F-8E03D859823D Q38252591-4D14D7E8-92EA-4C26-992A-CA289DC77CD4 Q38673230-223642B4-712D-4EB1-9984-E5E7A9A0A843 Q38735845-98A31EA1-ACAD-4E0D-8149-B095488E4477 Q38740479-C3F47678-9D4C-448F-8195-66606622F1E1 Q38750226-02FB2D75-4514-494E-B2A6-1CF94E20411D Q38817737-AAF6F302-AA52-4EE0-9016-3881C5EFFF76 Q38978952-0320BBC8-8566-4EC1-94D7-6D16F68AB30E Q39367115-FBBA1471-AFFF-4891-8465-1C55A6505D61

P2860

Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction

http://www.wikidata.org/entity/Q27677509

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Targeting the von Hippel–Linda ...... upt the VHL/HIF-1α Interaction

@ast

Targeting the von Hippel–Linda ...... upt the VHL/HIF-1α Interaction

@en

Targeting the von Hippel–Linda ...... upt the VHL/HIF-1α Interaction

@nl

type

label

Targeting the von Hippel–Linda ...... upt the VHL/HIF-1α Interaction

@ast

Targeting the von Hippel–Linda ...... upt the VHL/HIF-1α Interaction

@en

Targeting the von Hippel–Linda ...... upt the VHL/HIF-1α Interaction

@nl

prefLabel

Targeting the von Hippel–Linda ...... upt the VHL/HIF-1α Interaction

@ast

Targeting the von Hippel–Linda ...... upt the VHL/HIF-1α Interaction

@en

Targeting the von Hippel–Linda ...... upt the VHL/HIF-1α Interaction

@nl

P1433

Q27677509-495B6324-C992-4E27-913E-E91585B58FB2

P1476

Q27677509-E548C05F-EFB8-44C6-B9F1-EF25E16BA2BF

P2093

Q27677509-49C2A309-7013-4BC6-B3E9-54C1183AED36

Q27677509-7C3D329E-4603-4F36-8C9C-5B3059C23909

Q27677509-A5D242B3-F01A-46F4-B808-5C82B6FD9DE1

Q27677509-C3F48B8A-D325-4E8A-BF58-98705EE778C6

Q27677509-DAE2F0A9-65B1-4E9A-96CD-1A812A333524

Q27677509-E06542E1-9166-4E80-AD54-4657CD0328A3

P2860

Q27677509-00C6D203-B7B0-48A8-A9C8-6892458AB56E

Q27677509-08A46058-5D40-4BFD-ACB3-14C9AA786FFE

Q27677509-0D37F62F-28E7-4527-A855-57448E0D36D3

Q27677509-19BFE7A3-B60E-4D3F-BDEE-5C53D68F1E06

Q27677509-49E40D44-CBB7-44A9-8C88-F05DB6792408

Q27677509-4CF8FA18-F9E4-41A4-8AA7-7609CB84E69E

Q27677509-4FEFFE48-6D95-45C5-955B-1030B0EF5AFB

Q27677509-5B2BF85C-DF59-49AB-AB35-CD8A13A43C4F

Q27677509-5D5F5A12-777F-44AB-A489-1A3DE9F51C53

Q27677509-618BBA83-6E4D-4D10-9A56-09445DE2D86E

P304

Q27677509-C535D603-049B-4DC6-B24C-92AF8A997DF2

P31

Q27677509-F4F9C4B5-03C6-454D-B628-9E14FFA4C6A5

P3181

Q27677509-67909282-7493-42E6-981B-B2FA97E0A436

P356

Q27677509-D9DE6C86-69F1-4C9E-83D9-78269618BF51

P407

Q27677509-9401E5A6-A939-47AA-92D7-23D82AEEFCF2

P433

Q27677509-FD87D55E-642B-46D4-B69B-35A02BB2B917

P478

Q27677509-3C7DF9A8-F476-4B6C-847E-B10038AD206D

P50

Q27677509-5954D008-A567-405B-B0F9-B6A2A60FC2D5

Q27677509-85E5E986-E47E-4AC6-9164-E12EBB036470

Q27677509-E987F5FE-00E7-40E8-977D-81B908D46C74

P577

Q27677509-7FCADDB0-4D51-426E-8DFB-9CDFC6715FC4

P5875

Q27677509-A26A21C7-2A14-45AE-B65B-EEB9CEBBF00C

P698

Q27677509-A3C62253-686C-4402-9E38-8AD62DDE5A04

P921

Q27677509-80E2360B-FF90-48CD-AB6A-2280E9C27D26

P932

Q27677509-C67CF496-71E2-49E7-8C26-098581F76AFA

P3181

P356

P1433

Journal of the American Chemical Society

P1476

Targeting the von Hippel–Linda ...... upt the VHL/HIF-1α Interaction

@en

P2093

Craig M Crews

http://www.w3.org/2001/XMLSchema#string

Dennis L Buckley

http://www.w3.org/2001/XMLSchema#string

Devin J Noblin

http://www.w3.org/2001/XMLSchema#string

Hyun Seop Tae

http://www.w3.org/2001/XMLSchema#string

Julien Michel

http://www.w3.org/2001/XMLSchema#string

Peter C Gareiss

http://www.w3.org/2001/XMLSchema#string

P2860

Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling

Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL

Total synthesis of lysobactin

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

An allosteric inhibitor of substrate recognition by the SCFCdc4 ubiquitin ligase

HIF prolyl hydroxylase inhibitors for anemia

Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase

Reaching for high-hanging fruit in drug discovery at protein-protein interfaces

Oxygen sensing by HIF hydroxylases

Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water.

P304

4465-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2676697

http://www.w3.org/2001/XMLSchema#string

P356

10.1021/JA209924V

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

134

http://www.w3.org/2001/XMLSchema#string

P50

William L. Jorgensen

P577

2012-03-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221865857

http://www.w3.org/2001/XMLSchema#string

P698

22369643

http://www.w3.org/2001/XMLSchema#string

P921

P932

3448299

http://www.w3.org/2001/XMLSchema#string